α7 Nicotinic Acetylcholine Receptor as a Potential Therapeutic Target for Schizophrenia

被引：46

作者：

Ishikawa, Masatomo ^{[1
]}

Hashimoto, Kenji ^{[1
]}

机构：

[1] Chiba Univ, Ctr Forens Mental Hlth, Div Clin Neurosci, Chiba 2608670, Japan

来源：

CURRENT PHARMACEUTICAL DESIGN | 2011年 / 17卷 / 02期

关键词：

alpha 7 nicotinic acetylcholine receptors; schizophrenia; smoking; nicotine; P50 auditory evoked potential suppression; agonists; allosteric modulators; VITRO PHARMACOLOGICAL CHARACTERIZATION; POSITIVE ALLOSTERIC MODULATOR; INDUCED COGNITIVE DEFICITS; REPEATED AUDITORY-STIMULI; IN-VIVO CHARACTERIZATION; MIDBRAIN DOPAMINE AREAS; CIGARETTE-SMOKING; P50; SUPPRESSION; PARTIAL AGONIST; DBA/2; MICE;

D O I：

10.2174/138161211795049561

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Accumulating evidence suggests that the alpha 7 subtype of nicotinic acetylcholine receptors (nAChRs) plays a role in the pathophysiology of schizophrenia. Deficits in auditory P50 evoked potential suppression in patients with schizophrenia are associated with decreased density of alpha 7 nAChRs in the brain. Some agonists (e. g., DMXB-A and tropisetron) at alpha 7 nAChRs can improve P50 deficits in patients with schizophrenia. Together, these findings indicate that alpha 7 nAChRs are a potential therapeutic target for schizophrenia. Currently, a number of agonists and allosteric modulators at alpha 7 nAChRs are under development as potential therapeutic drugs. In this article, we review recent topics on alpha 7 nAChR agonists and alpha 7 nAChR allosteric modulators as therapeutic drugs for schizophrenia.

引用

页码：121 / 129

页数：9

共 50 条

[31] The Alpha7 nicotinic acetylcholine receptor is target for the treatment of skin fibrosis
Boehm, M.
Stegemann, A.
BRAIN BEHAVIOR AND IMMUNITY, 2019, 81 : 49 - 50
[32] The α7 Nicotinic Acetylcholine Receptor: A Promising Target for the Treatment of Fibrotic Skin Disorders
Stegemann, Agatha
Flis, Damian
Ziolkowski, Wieslaw
Distler, Joerg H. W.
Steinbrink, Kerstin
Boehm, Markus
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (12) : 2371 - 2379
[33] Nicotinic Acetylcholine Receptors are Possible Therapeutic Targets for Schizophrenia
Kohnomi, Shuntaro
Suemaru, Katsuya
Kawasaki, Hiromu
Choshi, Tominari
Hibino, Satoshi
Araki, Hiroaki
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2009, 129 (02): : 197 - 201
[34] Physiologic Functions and Therapeutic Applications of α7 Nicotinic Acetylcholine Receptor in Brain Disorders
Lee, Chien-Hsing
Hung, Shih-Ya
PHARMACEUTICS, 2023, 15 (01)
[35] A reversible model of the cognitive impairment associated with schizophrenia in monkeys: Potential therapeutic effects of two nicotinic acetylcholine receptor agonists
Buccafusco, Jerry J.
Terry, Alvin V., Jr.
BIOCHEMICAL PHARMACOLOGY, 2009, 78 (07) : 852 - 862
[36] POSITIVE ALLOSTERIC MODULATION OF THE A7 NICOTINIC ACETYLCHOLINE RECEPTOR AS A THERAPEUTIC FOR TBI
Atkins, Coleen
Sangadi, Dinesh
Sangadi, Akhila
Martinez, Orlando
Sanchez, Chantal
Placeres-Uray, Fabiola
Titus, David
Johnstone, Timothy
Hogenkamp, Derk
Gee, Kelvin
JOURNAL OF NEUROTRAUMA, 2021, 38 (14) : A81 - A82
[37] Therapeutic Targeting of α7 Nicotinic Acetylcholine Receptors
Papke, Roger L.
Horenstein, Nicole A.
PHARMACOLOGICAL REVIEWS, 2021, 73 (03) : 1118 - 1149
[38] α7 nicotinic acetylcholine receptor (α7 nAChR) agonists or antagonists as potential cognition enhancers?
Van Goethem, N. P.
Prickaerts, J.
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S48 - S49
[39] Feasibility and Importance of the α7 Nicotinic Acetylcholine Receptor (α7nAChR) as Target for PET Imaging
Deuther-Conrad, W.
Teodoro, R.
Scheunemann, M.
Roetering, S.
Patt, M.
Kranz, M.
Donat, C. K.
Xiong, G.
Fischer, S.
Bucerius, J.
Peters, D.
Cumming, P.
Steinbach, J.
Sabri, O.
Bruse, P.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S209 - S210
[40] Nicotinic acetylcholine receptor subtype expression, function, and pharmacology: Therapeutic potential of α-conotoxins
Tae, Han-Shen
Adams, David J.
PHARMACOLOGICAL RESEARCH, 2023, 191

← 1 2 3 4 5 →